A. Per the Infectious Diseases Society of America (IDSA) Guidelines, rapid influenza diagnostic tests (RIDTs) are recommended over rapid molecular assays for outpatients due to higher test sensitivity. B. Per the CDC, if influenza is clinically diagnosed, clinicians should not wait for the results of testing in patients at high risk for severe influenza before initiating antiviral therapy. C. When influenza prevalence is relatively high, false-positive results are more likely. D. Multiplex polymerase chain reaction (PCR) tests for influenza and COVID-19 are recommended for research only.

A. Oseltamivir reduces the duration of uncomplicated influenza by an average of 2 days in healthy outpatients if initiated ≤48 hours from symptom onset. B. The most common adverse reactions associated with the use of oseltamivir are nausea and vomiting. C. Earlier administration of neuraminidase inhibitors from time of symptom onset results in a shorter duration of illness. D. Per the CDC, oseltamivir and zanamivir can each be prescribed at a 7-day course for antiviral chemoprophylaxis of influenza.

A. Among high-risk patients with influenza B, baloxavir had a similar time to the improvement of influenza symptoms (TTIIS) compared with oseltamivir. B. Baloxavir was associated with a faster decline in viral shedding, starting from 1 day after treatment initiation, than placebo or oseltamivir. C. Baloxavir is FDA-approved to treat uncomplicated acute influenza in patients at least 5 years of age who have been symptomatic for <48 hours. D. Baloxavir, as compared with oseltamivir, was associated with a higher rate of gastrointestinal adverse effects in the CAPSTONE clinical trials.

A. 10% to 30% B. 30% to 50% C. 50% to 70% D. 70% to 90%